Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Arquitos Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Arquitos Capital Management focuses on high-conviction value and special situation investments where key decision makers possess significant skin in the game."
Arquitos Capital Management focuses on high-conviction value and special situation investments where key decision makers possess significant skin in the game. The portfolio is centered around five major holdings—Liquidia, Vistry Group, Lifecore Biomedical, ENDI, and Nam Tai Property—each benefiting from strong corporate alignment, key insider buying, or activist involvement. Performance during 2023 was driven by significant positive developments, including patent litigation victories for Liquidia and operational model transitions leading to heavy share buybacks at Vistry. Management views these core holdings as entering a harvesting phase, characterized by defined operational catalysts, potential corporate sale processes, or substantial market share gains. Risk management centers on alignment with insiders who hold material economic stakes, rather than broad macroeconomic hedging or short positions.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
Growth Outlook
Risk Appetite
Capital Deployment
Forward Guidance
Language Signal
Perceived Risk
Opportunity Density
Time Horizon